Navigating a cancer diagnosis is daunting, and patient advocacy groups are there to help. When Dusty was diagnosed with #NeuroendocrineTumors (NET), educational resources from these groups made NET research more accessible and allowed Dusty to have informed conversations with her healthcare providers about her care. #WorldCancerResearchDay
About us
Every Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. As a diverse, growing team, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. We take pride in our shared purpose, knowing the magnitude of our impact expands with every medicine we create and every form of cancer tumor type we treat. After operating in the challenging biotech sector for nearly three decades, we've evolved into a multi-platform cancer company with a proven track record of resiliency in the face of adversity. The success of our flagship commercial product set us up on our journey to discover and develop next-generation cancer treatments, driven by our relentless pursuit of results for the patients we serve. Cancer is our cause. Make it yours, too. Please see our Community Guidelines: bit.ly/4iBzJU0 For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
- Website
-
http://www.exelixis.com
External link for Exelixis
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Alameda, California
- Type
- Public Company
- Founded
- 1994
Locations
-
Primary
Get directions
1851 Harbor Bay Pkwy
Alameda, California 94502, US
Employees at Exelixis
-
James C Wong
Executive Director - IT Technical Services at Exelixis
-
Dana Aftab
-
Ursula Vitt, DVM, PMP
Impactful Leadership of Cross Functional Teams | Drug Development from Research to Approval | Biologics & Small Molecules | Oncology, Neuroscience…
-
Jags Vazirani
Life Sciences Business Development and Strategy Leader
Updates
-
Staying curious is an essential part of working in biotech, and Tsui Chern Cheah, MBS, MBA does just that. Hear about her interests inside and outside the workplace and how they contribute to advancing patient care. #WhyWeExel
-
Through lifestyle changes, early screenings, vaccinations and education, cases of #LiverCancer may be reduced. Our partner organization Blue Faery: The Adrienne Wilson Liver Cancer Association's HCC Lunch & Learn in Dallas will provide communities with actionable knowledge and preventive tools. Mark your calendar: September 27, 2025, from 10 a.m. until 3 p.m. CDT. Register today: bit.ly/4n6oO7T.
𝗙𝗥𝗢𝗠 𝗙𝗔𝗧𝗧𝗬 𝗟𝗜𝗩𝗘𝗥 𝗧𝗢 𝗟𝗜𝗩𝗘𝗥 𝗖𝗔𝗡𝗖𝗘𝗥! Fatty liver disease affects about a third of people worldwide. For some, it worsens into MASH, a more dangerous stage that 𝘀𝗰𝗮𝗿𝘀 𝘁𝗵𝗲 𝗹𝗶𝘃𝗲𝗿 𝗮𝗻𝗱 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗹𝗶𝘃𝗲𝗿 𝗰𝗮𝗻𝗰𝗲𝗿 𝗶𝗳 𝘂𝗻𝘁𝗿𝗲𝗮𝘁𝗲𝗱. Understanding metabolic liver disease is essential for everyone—not just clinicians. That's why we are hosting a 𝙛𝙧𝙚𝙚 𝙃𝘾𝘾 𝙇𝙪𝙣𝙘𝙝 𝙖𝙣𝙙 𝙇𝙚𝙖𝙧𝙣 𝙞𝙣 𝘿𝙖𝙡𝙡𝙖𝙨 on September 27. We'll discuss risk factors, lifestyle changes, and resources available to our community. ▶️ Register and share: https://vist.ly/43vp2. #liver #nonprofit #oncology
-
-
When Dusty was diagnosed with #NeuroendocrineTumors (NET), her loved ones were there to support her and ensure she never lost her sense of self throughout her #cancer journey. The act of ensuring your friends and family are receiving the medical care they need can make all the difference in a health journey. #TakeALovedOneToTheDoctorDay is a reminder to be there for someone in the way Dusty's friends were there for her.
-
September is #ThyroidCancerAwarenessMonth, and patient advocacy organization, ThyCa: Thyroid Cancer Survivors' Association, Inc. provides free educational materials to support early detection and more. Learn about thyroid cancer signs and symptoms and find resources to help spread #ThyroidCancer awareness here: bit.ly/4g0YJEs.